Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26.6 HKD | +7.26% | +16.41% | -31.97% |
04-11 | China stocks rise as commodities shine; Hong Kong snaps winning streak | RE |
04-03 | Alibaba Health Refutes Rumors of Purchase of Telemedicine Platform HaoDF | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 35.31 times its estimated earnings per share for the ongoing year.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-31.97% | 10.84B | B | ||
-32.21% | 15.27B | B- | ||
-30.42% | 6.06B | B | ||
+8.14% | 6.04B | C | ||
-11.41% | 5.86B | C+ | ||
-0.88% | 4.71B | D- | ||
+52.19% | 4.29B | - | C | |
-12.31% | 3.61B | B | ||
-14.86% | 3.33B | C- | ||
-6.93% | 3.01B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 6618 Stock
- Ratings JD Health International Inc.